Compare Bristol-Myers Squibb Co (BMY) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Paychex, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.89 (market cap $129.94B), while Paychex, Inc. trades at $119.23 (market cap $43.14B). The key difference: Bristol-Myers Squibb Co is far larger — about 3× Paychex, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | PAYX | |
|---|---|---|
Market Cap | $129.94B | $43.14B |
Sector | Health | Industrials |
52-Week High | $65.89 | $140.81 |
52-Week Low | $42.60 | $85.57 |
Enterprise Value | $163.92B | $46.63B |
Dividend Yield | 3.96% | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Paychex (PAYX) trades at $121.18, up 0.95% with a bullish technical outlook and strong fundamentals. The company maintains robust profitability with 27.03% net margins and consistent earnings beats. Recent expansion of WISE platform and steady small business employment trends support growth. Technical indicators show bullish momentum with support at $120 and resistance at $122.
PAYX offers stable dividend income and consistent execution but faces valuation concerns with P/E of 24.81 above sector averages. Analyst consensus remains cautious with 63% hold ratings. Key risks include economic sensitivity and competitive pressures in HR services. Upside depends on continued market share gains and margin maintenance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
